Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review

Retrieved on: 2023-01-07 03:23:01

Tags for this article:

Click the tags to see associated articles and topics

Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review. View article details on hiswai:

Excerpt

The FDA has accepted Roche Holdings AG's (OTC: RHHBY) Biologics License Application (BLA) and granted priority review for glofitamab for relapsed ...

Article found on: www.yahoo.com